New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 25, 2014
08:03 EDTSPNCSpectranetics price target raised to $30 from $24 at Stifel
Stifel increased its price target on Spectranetics after the company announced positive results from its EXCITE ISR clinical trial. The firm sees the results as a major milestone for Spectranetics and keeps a Buy rating on the shares.
News For SPNC From The Last 14 Days
Check below for free stories on SPNC the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
There are no results for SPNC

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use